Hematopoietic cell transplantation after CD19 CAR T cell-induced ALL remission confers leukemia-free survival advantage
Long-term remissions after CD19 chimeric antigen receptor (CAR) T cell therapy for refractory/relapsed CD19+ B cell acute lymphoblastic leukemia (B-ALL) are elusive.1-6 A high percentage of subjects achieve initial complete remission (CR), but half of subjects experience a recurrence of disease within 6-18 months from CAR T cell infusion.1, 4, 7
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Corinne Summers, Qian Vicky Wu, Colleen Annesley, Marie Bleakley, Ann Dahlberg, Prabha Narayanaswamy, Wenjun Huang, Jenna Voutsinas, Adam Brand, Wendy Leisenring, Michael C. Jensen, Julie R. Park, Rebecca A. Gardner Tags: HCT post CAR T cell remission confers LFS benefit Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Biology | Hematology | Leukemia | Transplants